Tasrif has developed and patented a platform targeting PVR, a receptor found in numerous cancers. Tasrif wishes to advance the platform to a clinical stage and IND filing. A minimum of 3Million USD is needed to advance the platform prior to Series A or Exit to Pharma.
Ready to Ask For Funding for your company?
Post a Funding Request